ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1946

Fast-Track Giant Cell Arteritis Clinic Experience in the United States

Mark Matza1, Minna Kohler2, John H. Stone3 and Sebastian Unizony1, 1Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Harvard Medical School, Boston, MA, 3Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2020

Keywords: giant cell arteritis, Ultrasound, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Fast-track clinics incorporating ultrasound into the initial evaluation of patients suspected of having giant cell arteritis (GCA) have been implemented throughout Europe leading to reduced incidence of blindness and decreased overall cost of care. Ultrasound is now recommended as one of the initial diagnostic modalities for GCA, assuming availability and expertise per EULAR guidelines. In the United States, the use of ultrasound for GCA diagnosis has been limited to date. Here we report our fast-track GCA clinic experience at Massachusetts General Hospital.

Methods: A fast-track GCA clinic was developed at our tertiary care academic medical center which serves as a referral center for GCA patients. A standardized algorithm was created for referred patients with suspected GCA. Clinical evaluation and a dedicated ultrasound exam of the bilateral temporal and axillary arteries were completed in a single clinic session within 48 hours of referral if the patient was able. Bilateral common superficial, parietal, and frontal branches of the temporal arteries were evaluated for both halo and compression signs, and bilateral axillary arteries for halo sign. Clinical evaluation and ultrasound exam were performed and interpreted by one rheumatologist (MAM). Ultrasound images were reviewed separately by a blinded rheumatologist (MJK), both with expertise in vasculitis ultrasound.

Results: Between September 2019 and March 2020, 18 patients were evaluated in the fast-track GCA clinic. Overall, 15 patients (83%) were seen within 48 hours, 11 patients (61%) within 24 hours and 2 patients within 1 hour of referral. Mean age was 72 years, 67% were female and 83% were Caucasian (17% Hispanic). Temporal headache was reported by 89% of patients. Mean ESR was 24.7 mm/h, mean CRP was 40.6 mg/L, and 6 patients had acute phase reactants within normal limits. Four patients (22%) had a positive temporal (n = 3) or axillary (n = 1) artery ultrasound confirmed by the blinded reviewer. Three of the 4 patients with a positive ultrasound also had a positive temporal artery biopsy (TAB). The remaining patient had relapsing GCA previously diagnosed with TAB, therefore a new biopsy was not pursued. In total, 10 patients underwent TAB after ultrasound. Mean time from fast-track evaluation to TAB was 6 days. There were no conflicting results between ultrasound and TAB. Four patients with negative results on both ultrasound and TAB and one additional patient who declined TAB went on to be treated for GCA given clinical suspicion. The remaining patients were diagnosed with headache (n = 5), infection (n = 2), cardioembolic transient vision loss (n = 1) and vasculitis not otherwise specified (n = 1). Of note, 1 patient with classic symptoms of GCA and a clearly positive ultrasound was found to have normal acute phase reactants and positive TAB. No patients developed vision loss attributed to GCA.

Conclusion: Ultrasound at the point of care is an effective diagnostic tool in GCA, assuming adequate training and availability. TAB can be obtained to confirm ultrasound findings particularly during the initial phase of a fast-track clinic. For a subset of patients with negative ultrasound and TAB, the diagnosis of GCA was made on clinical grounds.


Disclosure: M. Matza, None; M. Kohler, None; J. Stone, Roche, 2, 5, Genentech, 2, 5; S. Unizony, Genentech, 2, Janssen, 2, 5, Sanofi, 5, Kiniksa, 5.

To cite this abstract in AMA style:

Matza M, Kohler M, Stone J, Unizony S. Fast-Track Giant Cell Arteritis Clinic Experience in the United States [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/fast-track-giant-cell-arteritis-clinic-experience-in-the-united-states/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fast-track-giant-cell-arteritis-clinic-experience-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology